Tran Tu M, Najafi Mehdi, Ambros Tadeu, Pulido Jose S, Ustun Celalettin, Koozekanani Dara
Department of Ophthalmology and Visual Neuroscience, University of Minnesota, Minneapolis, MN, USA.
Oncology/Hematology Service, Essentia Health, Fargo, ND, USA.
Am J Ophthalmol Case Rep. 2020 Feb 4;18:100614. doi: 10.1016/j.ajoc.2020.100614. eCollection 2020 Jun.
To report a rare case of a unilateral choroidal mast cell infiltration in a patient with aggressive systemic mastocytosis (ASM).
The patient is a man in his fifties with a diagnosis of ASM. He developed visual complaints in the right eye associated with an area of subretinal fluid on fundus examination. Visual acuity at presentation was 20/150 in the right eye and 20/25 in the left eye. After ophthalmic and radiologic imaging workup, the patient was diagnosed with presumed choroidal mast cell infiltrate. The index of suspicion was high due to the prior ASM diagnosis. External beam radiation and intravitreal injection treatments were offered but the patient declined. The patient was switched from interferon to a new targeted systemic therapy for ASM, midostaurin. Despite some mixed, temporary response in systemic symptoms/signs of ASM at four months, the choroidal lesion and subretinal fluid were stable with visual acuity at 20/125.
Mast cell choroidal infiltration in ASM should be considered as part of the differential with acute/subacute vision changes. Diagnosis requires exclusion of other possibilities with ocular imaging and in this case, monitoring for development of other malignancies in which there were none. Midostaurin's ocular response was not on par with systemic response. Additional localized ocular therapies may be required.
报告一例侵袭性系统性肥大细胞增多症(ASM)患者单侧脉络膜肥大细胞浸润的罕见病例。
患者为一名五十多岁男性,诊断为ASM。他出现右眼视力问题,眼底检查发现视网膜下液区域。就诊时右眼视力为20/150,左眼视力为20/25。经过眼科和放射影像学检查,患者被诊断为疑似脉络膜肥大细胞浸润。由于之前的ASM诊断,怀疑指数很高。提供了外照射放疗和玻璃体内注射治疗,但患者拒绝了。患者从干扰素转换为一种新的针对ASM的靶向全身治疗药物米哚妥林。尽管在四个月时ASM的全身症状/体征有一些混合的、暂时的反应,但脉络膜病变和视网膜下液稳定,视力为20/125。
ASM中的肥大细胞脉络膜浸润应被视为急性/亚急性视力变化鉴别诊断的一部分。诊断需要通过眼部成像排除其他可能性,在本病例中,未发现其他恶性肿瘤。米哚妥林的眼部反应与全身反应不一致。可能需要额外的局部眼部治疗。